Genmab to acquire ADC maker

Genmab is slated to acquire antibody-drug-conjugate (ADC) developer ProfoundBio for $1.8 billion. The Danish pharma firm will gain three clinical-stage drug candidates: rinatabart sesutecan, an ADC that targets folate receptor α in ovarian cancer and other solid tumors; PRO1160, an ADC that targets CD70 in kidney and nasopharyngeal cancers and non-Hodgkin's lymphoma; and PRO1107, an ADC that targets the enzyme PTK7 in solid tumors . Genmab will also inherit ProfoundBio's ADC development platforms.